Canopy Growth Corp (CGC) - Net Assets
Based on the latest financial reports, Canopy Growth Corp (CGC) has net assets worth $688.63 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.10 Billion) and total liabilities ($415.29 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check CGC PP&E to net assets ratio to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $688.63 Million |
| % of Total Assets | 62.38% |
| Annual Growth Rate | 55.77% |
| 5-Year Change | -80.73% |
| 10-Year Change | 13.48% |
| Growth Volatility | 220.19 |
Canopy Growth Corp - Net Assets Trend (2010–2026)
This chart illustrates how Canopy Growth Corp's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see Canopy Growth Corp market capitalisation.
Annual Net Assets for Canopy Growth Corp (2010–2026)
The table below shows the annual net assets of Canopy Growth Corp from 2010 to 2026. Also explore how fast is Canopy Growth Corp growing its equity to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2026-03-31 | $697.59 Million | +43.18% |
| 2025-03-31 | $487.21 Million | -2.66% |
| 2024-03-31 | $500.51 Million | -34.15% |
| 2023-03-31 | $760.02 Million | -79.01% |
| 2022-03-31 | $3.62 Billion | -0.04% |
| 2021-03-31 | $3.62 Billion | -0.44% |
| 2020-03-31 | $3.64 Billion | -49.76% |
| 2019-03-31 | $7.24 Billion | +482.47% |
| 2018-03-31 | $1.24 Billion | +102.24% |
| 2017-03-31 | $614.74 Million | +396.62% |
| 2016-03-31 | $123.78 Million | +198.93% |
| 2015-03-31 | $41.41 Million | +91.11% |
| 2014-12-31 | $21.67 Million | +465.27% |
| 2014-03-31 | $3.83 Million | +671.25% |
| 2013-03-31 | $497.01K | -7.56% |
| 2012-03-31 | $537.65K | -3.40% |
| 2011-03-31 | $556.60K | -4.14% |
| 2010-03-31 | $580.67K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Canopy Growth Corp's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1113820008200.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (March 2026)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $9.23 Billion | 1323.63% |
| Other Comprehensive Income | $10.53 Million | 1.51% |
| Other Components | $2.59 Billion | 371.52% |
| Total Equity | $697.59 Million | 100.00% |
Canopy Growth Corp Competitors by Market Cap
The table below lists competitors of Canopy Growth Corp ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
BENZ MINING CORP CDI/1
F:1VU0
|
$397.29 Million |
|
PowerFleet, Inc.
NASDAQ:AIOT
|
$397.31 Million |
|
Scimee Sci &Tech Co Ltd
SHE:300425
|
$397.33 Million |
|
Nanjing Shenghang Shipping Co Ltd
SHE:001205
|
$397.53 Million |
|
Shenzhen Genvict Technologies Co Ltd
SHE:002869
|
$397.13 Million |
|
Jiangsu Canopus Wisdom Medical Technology Co. Ltd. A
SHE:301290
|
$396.95 Million |
|
Axis Bank Ltd GDR
IL:AXB
|
$396.66 Million |
|
LF Corp
KO:093050
|
$396.66 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Canopy Growth Corp's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2025 to 2026, total equity changed from 487,213,000 to 697,594,000, a change of 210,381,000 (43.2%).
- Net loss of 262,908,000 reduced equity.
- New share issuances of 374,171,000 increased equity.
- Other comprehensive income increased equity by 9,995,000.
- Other factors increased equity by 89,123,000.
Equity Change Factors (2025 to 2026)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-262.91 Million | -37.69% |
| Share Issuances | $374.17 Million | +53.64% |
| Other Comprehensive Income | $9.99 Million | +1.43% |
| Other Changes | $89.12 Million | +12.78% |
| Total Change | $- | 43.18% |
Book Value vs Market Value Analysis
This analysis compares Canopy Growth Corp's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.01x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 1.62x to 4.01x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2010-03-31 | $0.58 | $0.94 | x |
| 2011-03-31 | $0.56 | $0.94 | x |
| 2012-03-31 | $0.54 | $0.94 | x |
| 2013-03-31 | $0.50 | $0.94 | x |
| 2014-03-31 | $3.83 | $0.94 | x |
| 2015-03-31 | $1.38 | $0.94 | x |
| 2016-03-31 | $1.61 | $0.94 | x |
| 2017-03-31 | $5.38 | $0.94 | x |
| 2018-03-31 | $6.54 | $0.94 | x |
| 2019-03-31 | $20.09 | $0.94 | x |
| 2020-03-31 | $9.64 | $0.94 | x |
| 2021-03-31 | $9.27 | $0.94 | x |
| 2022-03-31 | $91.58 | $0.94 | x |
| 2023-03-31 | $16.36 | $0.94 | x |
| 2024-03-31 | $6.69 | $0.94 | x |
| 2025-03-31 | $4.53 | $0.94 | x |
| 2026-03-31 | $0.23 | $0.94 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Canopy Growth Corp utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -37.69%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -92.38%
- • Asset Turnover: 0.25x
- • Equity Multiplier: 1.60x
- Recent ROE (-37.69%) is above the historical average (-53.06%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2010 | -4.64% | -4903.10% | 0.00x | 1.01x | $-84.98K |
| 2011 | -4.32% | -536.27% | 0.01x | 1.01x | $-79.73K |
| 2012 | -3.98% | -449.15% | 0.01x | 1.01x | $-75.16K |
| 2013 | -13.00% | -1559.07% | 0.01x | 1.02x | $-114.31K |
| 2014 | -24.34% | 0.00% | 0.00x | 1.34x | $-1.32 Million |
| 2014 | -41.22% | -779.58% | 0.04x | 1.20x | $-11.10 Million |
| 2015 | -21.57% | -470.87% | 0.04x | 1.15x | $-13.07 Million |
| 2016 | -2.82% | -27.53% | 0.09x | 1.16x | $-15.87 Million |
| 2017 | -1.18% | -18.85% | 0.06x | 1.06x | $-71.50 Million |
| 2018 | -5.81% | -86.32% | 0.05x | 1.24x | $-183.16 Million |
| 2019 | -10.86% | -325.30% | 0.03x | 1.29x | $-1.41 Billion |
| 2020 | -38.49% | -331.35% | 0.08x | 1.40x | $-1.66 Billion |
| 2021 | -50.12% | -319.20% | 0.08x | 1.96x | $-2.09 Billion |
| 2022 | -8.65% | -65.18% | 0.08x | 1.56x | $-668.40 Million |
| 2023 | -432.23% | -983.68% | 0.14x | 3.22x | $-3.35 Billion |
| 2024 | -131.36% | -221.19% | 0.23x | 2.60x | $-707.31 Million |
| 2025 | -122.76% | -222.35% | 0.29x | 1.88x | $-646.84 Million |
| 2026 | -37.69% | -92.38% | 0.25x | 1.60x | $-332.67 Million |
Industry Comparison
This section compares Canopy Growth Corp's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $180,509,986
- Average return on equity (ROE) among peers: -187.74%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Canopy Growth Corp (CGC) | $688.63 Million | -4.64% | 0.60x | $397.27 Million |
| Aurora Cannabis Inc (ACB) | $219.71 Million | -5.90% | 0.47x | $236.15 Million |
| ADC Therapeutics SA (ADCT) | $-185.83 Million | 0.00% | 0.00x | $134.82 Million |
| Akanda Corp (AKAN) | $-5.03 Million | 0.00% | 0.00x | $1.51 Million |
| Akebia Ther (AKBA) | $5.23 Million | -1801.64% | 67.08x | $239.89 Million |
| Alkermes Plc (ALKS) | $853.85 Million | 2.93% | 0.68x | $7.84 Billion |
| Amylyx Pharmaceuticals Inc (AMLX) | $-151.17 Million | 0.00% | 0.00x | $3.58 Billion |
| Amphastar P (AMPH) | $281.86 Million | -3.80% | 0.38x | $980.07 Million |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $346.79 Million | -104.36% | 9.57x | $5.96 Billion |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $344.93 Million | 26.40% | 10.61x | $3.57 Billion |
| Anika Therapeutics Inc (ANIK) | $94.76 Million | 8.93% | 0.40x | $279.44 Million |
About Canopy Growth Corp
Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and cannabis-related products for medical and adult use in Canada, Germany, the United States, and internationally. The company operates through two segments, Cannabis and Storz & Bickel. It also provides vaporizers and accessories; dried flower and pre-rolled joints, oil, and … Read more